Black Diamond Therapeutics Inc
NASDAQ:BDTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Black Diamond Therapeutics Inc
NASDAQ:BDTX
|
US |
|
M
|
Merck KGaA
DUS:MRK
|
DE |
|
P
|
PNC Financial Services Group Inc
F:PNP
|
US |
|
G
|
General Dynamics Corp
BMV:GD
|
US |
|
B
|
Beforepay Group Ltd
ASX:B4P
|
AU |
|
C
|
CVS Health Corp
DUS:CVS
|
US |
|
B
|
Brady Corp
SWB:BRV
|
US |
|
C
|
China Oilfield Services Ltd
XMUN:CO9
|
CN |
|
C
|
Coloplast A/S
F:CBHD
|
DK |
|
M
|
Mitsubishi Estate Co Ltd
DUS:MES
|
JP |
|
R
|
Resonac Holdings Corp
DUS:SWD
|
JP |
|
M
|
Marathon Petroleum Corp
F:MPN
|
US |
|
R
|
Remgro Ltd
JSE:REM
|
ZA |
|
P
|
Persol Holdings Co Ltd
F:59R
|
JP |
|
Orrstown Financial Services Inc
F:OFR
|
US |
|
Z
|
Zen Corporation Group PCL
SET:ZEN
|
TH |
|
R
|
Ryanair Holdings PLC
F:RY4C
|
IE |
|
H
|
Heriot REIT Ltd
JSE:HET
|
ZA |
Wall St Price Targets
BDTX Price Targets Summary
Black Diamond Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for BDTX is 10.2 USD with a low forecast of 8.08 USD and a high forecast of 14.7 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BDTX's stock price target?
Price Target
10.2
USD
According to Wall Street analysts, the average 1-year price target for BDTX is 10.2 USD with a low forecast of 8.08 USD and a high forecast of 14.7 USD.
What is the Revenue forecast for Black Diamond Therapeutics Inc?
Projected CAGR
29%
The compound annual growth rate for Revenue over the next 8 years is 29%.
What is the Operating Income forecast for Black Diamond Therapeutics Inc?
Projected CAGR
39%
The compound annual growth rate for Operating Income over the next 8 years is 39%.
What is the Net Income forecast for Black Diamond Therapeutics Inc?
Projected CAGR
33%
The compound annual growth rate for Net Income over the next 8 years is 33%.
